Krka (KRK) Q2 2025 earnings summary

Executive summary

• Sales reached a record €1,048.5m in H1 2025, up 6–7% year-over-year, with 94% generated outside Slovenia and volume growth of 4%.

• Net profit rose 11% year-over-year to €246.7m, with a net profit margin of 23.5%.

• Operating profit (EBIT) increased 8% to €257.0m; EBITDA reached €303.3m, with margins of 24.5% and 28.9%.

• Sales grew in all regions except Overseas markets; prescription pharmaceuticals remained the main growth driver.

• Eleven new products were added, including nine prescription pharmaceuticals.

Financial highlights

• EBITDA margin at 28.9% and EBIT margin at 24.5% for H1 2025.

• Gross profit margin stable at 57.9%; net profit margin improved to 23.5%.

• Basic EPS rose 12% to €8.04; earnings per share (EPS) also reported at €16.07.

• Cash and cash equivalents rose 53% to €528.6m compared to year-end 2024.

• Market capitalization reached €6.3bn; share price surged 39.2% since year-end 2024.

Outlook and guidance

• FY2025 sales guidance set above €2,000m; net income guidance at €365m.

• CAPEX for 2025 planned at €150m, mainly for production expansion.

• Guidance for 2025 was raised in January, reflecting strong momentum.

• Employee headcount expected to rise by 1% for the year.

• Strategic update for 2026–2030 to be released with 9M 2025 results.